FOX vs IKT · P/E 13, rev $16.30B vs $215.2M cap
Fox Corp Class B (FOX) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
Fox Corp Class B (FOX) is a entertainment company listed on US.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported FOX revenue for 2025-06-30 was $16.30B. Net income was $2.29B. Revenue was up 16.6% from 2024-06-30 to 2025-06-30. FOX currently screens at market cap $24.49B and trailing P/E 13.0.
Latest reported IKT revenue for 2024-12-31 was $0. Net income was -$27.5M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. IKT currently screens at market cap $215.2M.
FOX currently screens at market cap $24.49B and trailing P/E 13.0. IKT currently screens at market cap $215.2M.
Not investment advice. Open the FOX and IKT stock pages for the full models.
Not investment advice.